Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
2,148
datasets available to search
ShareScore release 0.9.0
Dataset results
2,148 results for “HER2”
A Study to Evaluate the Efficacy and Safety of Pertuzumab + Trastuzumab + Docetaxel Versus Placebo + Trastuzumab + Docetaxel in Previously Untreated Human Epidermal Growth Factor Receptor 2 (HER2)-Pos
ClinicalTrials.gov study NCT02896855. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Efficacy and Safety Evaluating Study of CT-P6 in Her2 Positive Early Breast Cancer
ClinicalTrials.gov study NCT02162667. IPD Sharing: Not stated. Countries: 22. Publications: 3.
A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer
ClinicalTrials.gov study NCT02623972. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Study of Pertuzumab in Combination With Trastuzumab (Herceptin) and a Taxane in First-Line Treatment in Participants With Human Epidermal Growth Factor 2 (HER2)-Positive Advanced Breast Cancer
ClinicalTrials.gov study NCT01572038. IPD Sharing: Not stated. Countries: 39. Publications: 1.
Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer
ClinicalTrials.gov study NCT01036087. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Participants With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive and Hormone Receptor-Positive
ClinicalTrials.gov study NCT01491737. IPD Sharing: Not stated. Countries: 8. Publications: 1.
CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer
ClinicalTrials.gov study NCT01191697. IPD Sharing: Not stated. Countries: 1. Publications: 25.
Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 Gene Found in Their Tumors (MATCH - Subprotocol J)
ClinicalTrials.gov study NCT06136897. IPD Sharing: YES. Countries: 1. Publications: 1.
A Safety and Tolerability Study of Assisted and Self-Administered Subcutaneous (SC) Herceptin (Trastuzumab) as Adjuvant Therapy in Early Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast
ClinicalTrials.gov study NCT01566721. IPD Sharing: YES. Countries: 59. Publications: 2.
Vaccine Therapy in Treating Patients With Stage IV HLA-A2 and HER2 Positive Breast or Ovarian Cancer Receiving Trastuzumab
ClinicalTrials.gov study NCT00194714. IPD Sharing: Not stated. Countries: 1. Publications: 1.
HKI-272 for HER2-Positive Breast Cancer and Brain Metastases
ClinicalTrials.gov study NCT01494662. IPD Sharing: UNDECIDED. Countries: 1. Publications: 3.
Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax
ClinicalTrials.gov study NCT01570036. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Dasatinib In Combination With Trastuzumab And Paclitaxel In First Line Treatment Of Her2-Positive MBC Patients
ClinicalTrials.gov study NCT01306942. IPD Sharing: Not stated. Countries: 1. Publications: 2.
Neoadjuvant Carboplatin, Weekly Abraxane and Trastuzumab in HER2+ Breast Cancer
ClinicalTrials.gov study NCT00617942. IPD Sharing: Not stated. Countries: 1. Publications: 1.
A Study Of PF-05280014 [Trastuzumab-Pfizer] Or Herceptin® [Trastuzumab-EU] Plus Paclitaxel In HER2 Positive First Line Metastatic Breast Cancer Treatment (REFLECTIONS B327-02)
ClinicalTrials.gov study NCT01989676. IPD Sharing: YES. Countries: 24. Publications: 3.
Incidence and Severity of Diarrhea in Patients With HER2 Positive Breast Cancer Treated With Trastuzumab and Neratinib
ClinicalTrials.gov study NCT03094052. IPD Sharing: YES. Countries: 1. Publications: 10.
A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment
ClinicalTrials.gov study NCT01702571. IPD Sharing: Not stated. Countries: 43. Publications: 3.
Tucatinib, Trastuzumab, and Capecitabine for the Treatment of HER2+ LMD
ClinicalTrials.gov study NCT03501979. IPD Sharing: NO. Countries: 1. Publications: 0.
Real-World Observational Study to Describe Treatment Patterns in Patients With HER2-Positive Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer in East Asia
ClinicalTrials.gov study NCT05606094. IPD Sharing: YES. Countries: 4. Publications: 0.
A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breas
ClinicalTrials.gov study NCT04622319. IPD Sharing: YES. Countries: 31. Publications: 1.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.